CVS Caremark Updates Formularies to Prioritize Biosimilars, Targeting $0 Out‑of‑Pocket for Members

Why It Matters

The formulary changes represent a pivotal effort to curb the relentless rise in specialty drug spending, which has outpaced inflation for years. By positioning interchangeable biosimilars as the default choice, CVS Caremark not only reduces out‑of‑pocket costs for patients but also pressures manufacturers of brand biologics to reconsider pricing strategies. Wider biosimilar adoption could improve medication adherence, lower overall health‑care expenditures, and set a precedent for other large PBMs to use formulary design as a lever for affordability. For patients, the $0 cost‑sharing model removes a significant financial hurdle, potentially expanding access to life‑saving therapies for conditions like psoriasis, multiple sclerosis, and rare blood disorders. For the industry, the move underscores the growing commercial viability of biosimilars and may accelerate the pipeline of interchangeable products, fostering a more competitive and sustainable biologics market.

Key Takeaways

• CVS Caremark will implement formulary updates on July 1, 2026 to prefer interchangeable biosimilars
• Stelara® will be replaced by lower‑cost biosimilars Pyzchiva® and Yesintek®
• Members on the affected therapies will pay $0 out‑of‑pocket
• Biosimilar alternatives added for Tysabri® (Briumvi®, Tyruko®) and Soliris® (Epissami®)
• Updates were vetted by an independent Pharmacy & Therapeutics committee to ensure clinical parity

Pulse Analysis

CVS Caremark’s decision to embed interchangeable biosimilars into its template formularies reflects a strategic shift from passive coverage to active cost stewardship. Historically, PBMs have faced criticism for opaque rebate structures that often favor higher‑priced brand biologics. By foregrounding biosimilars, CVS signals a willingness to prioritize transparent, value‑based pricing over rebate‑driven incentives. This could reshape negotiations with manufacturers, as brand‑drug makers may need to offer deeper discounts or accelerate their own biosimilar pipelines to retain market share.

The $0 out‑of‑pocket promise is a calculated risk that leverages the PBM’s scale to negotiate favorable pricing terms while mitigating patient resistance. If utilization data confirm that members readily switch to the preferred biosimilars, CVS could achieve multi‑million‑dollar savings for its clients, reinforcing its value proposition in a crowded benefits‑management market. Competitors such as Express Scripts and OptumRx will likely feel pressure to replicate similar formulary tactics, potentially igniting a broader industry movement toward biosimilar‑first policies.

Long‑term, the initiative may accelerate the maturation of the U.S. biosimilar market, encouraging manufacturers to invest in interchangeable designs that meet the FDA’s stringent criteria. As more PBMs adopt comparable strategies, the cumulative effect could be a substantial compression of specialty drug spend, freeing resources for other areas of patient care and possibly influencing policy discussions around drug pricing reform.